A Phase 1, First-in-human Study of VX-668

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

NCT05361733 ·Status: RECRUITING ·Phase: PHASE1

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

NCT01597635 ·Status: COMPLETED ·Phase: PHASE2

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

NCT04385836 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

NCT03679598 ·Status: COMPLETED ·Phase: PHASE2

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

NCT01669421 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

NCT05785624 ·Status: TERMINATED ·Phase: PHASE2

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

NCT03287414 ·Status: TERMINATED ·Phase: PHASE2

Single and Multiple Ascending Dose Study of AER-01

NCT05862623 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

NCT02479139 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT00786201 ·Status: COMPLETED ·Phase: PHASE2

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729 ·Status: COMPLETED ·Phase: PHASE1

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

NCT03373903 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

NCT01909843 ·Status: COMPLETED ·Phase: PHASE1

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

NCT04926701 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects

NCT06918366 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of OsrhAAT or Placebo in Healthy Volunteers

NCT05315921 ·Status: UNKNOWN ·Phase: PHASE1

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis

NCT05722964 ·Status: COMPLETED ·Phase: PHASE2

Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System

NCT04946630 ·Status: COMPLETED ·Phase: NA

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

NCT02001688 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707 ·Status: COMPLETED ·Phase: PHASE2

NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

NCT06622668 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

NCT04488705 ·Status: COMPLETED ·Phase: PHASE1

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

NCT06049082 ·Status: RECRUITING ·Phase: PHASE1

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817 ·Status: COMPLETED ·Phase: PHASE2